Recruiting studies: Pik3Ca Related Overgrowth Spectrum

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of Proteus Syndrome and Related Congenital Disorders
Phase N/A · 1 location(s) · National Human Genome Research Institute (NHGRI) · NCT00001403 A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
Phase 2 · 2 location(s) · Murdoch Childrens Research Institute · NCT05983159 A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spe
Phase 2 · 34 location(s) · Relay Therapeutics, Inc. · NCT06789913 EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediat
Phase 2 · 35 location(s) · Novartis Pharmaceuticals · NCT06997588 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-r
Phase 1/Phase 2 · 15 location(s) · Haihe Biopharma Co., Ltd. · NCT06975618

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.